Malignant hyperthermia is a pharmacogenetic disease of skeletal muscle in which a life-threatening, hypermetabolic syndrome is induced by exposure of susceptible patients to halogenated general anaesthetics and/or
succinylcholine.
Dantrolene sodium, the only
drug effective for treatment of
malignant hyperthermia, has low water solubility that makes its clinical use difficult. The aim of this study was to investigate the potency of
azumolene, a 30-fold more water-soluble analogue, in comparison to the prototype
dantrolene sodium, on mammalian and human skeletal muscles. The twitches of extensor digitorum longus and soleus muscles from mice were inhibited by
azumolene with IC(50) of 2.8 +/- 0.8 and 2.4 +/- 0.6 microM, respectively. The IC(50) of
dantrolene sodium in these muscles was 1.6 +/- 0.4 and 3.5 +/- 1.2 microM, respectively, with no difference in comparison to
azumolene. Previous in vitro exposure of mouse soleus muscle to
azumolene and
dantrolene sodium (10 microM) significantly inhibited 8 mM
caffeine-induced
contractures.
Azumolene was just effective as
dantrolene sodium in relaxing
caffeine-induced
contractures of mouse soleus muscle.
Intravenous injection caused dose-dependent decreases in twitches of guinea pig gastrocnemius muscle with IC(50) of 1.2 +/- 0.1 and 1.5 +/- 0.2 mg/kg for
azumolene and
dantrolene sodium, respectively.
Azumolene, 10 microM, was effective in blocking and reversing
caffeine-induced
contracture of human
malignant hyperthermia susceptible skeletal muscle in vitro. These studies provide evidence that
azumolene is equipotent to
dantrolene sodium in blocking pharmacologic-induced muscle
contractures and that
azumolene should be efficacious for treatment/prevention of
malignant hyperthermia.